S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Summary

Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It may also stop the growth of tumor cells by stopping blood flow to the tumor. This phase II trial is studying how well sorafenib works in treating patients with recurrent or metastatic head and neck cance

Timeline

Start

2004-10

Primary completion

2006-05

Completion

—

Drugs

Indications